Bluebird Bio Inc. (NASDAQ:BLUE) has been assigned a $95.00 price objective by Piper Jaffray Cos. in a research report issued to clients and investors on Thursday. The brokerage presently has a a “buy” rating on the stock. Piper Jaffray Cos.’s price target would suggest a potential upside of 44.93% from the stock’s previous close.

BLUE has been the topic of several other reports. Roth Capital began coverage on shares of Bluebird Bio in a report on Thursday, September 22nd. They set a “buy” rating and a $87.00 price target on the stock. Maxim Group set a $85.00 price target on shares of Bluebird Bio and gave the company a “buy” rating in a report on Thursday, September 22nd. Zacks Investment Research cut shares of Bluebird Bio from a “hold” rating to a “sell” rating in a report on Wednesday, October 5th. Jefferies Group restated a “buy” rating and set a $80.00 price target on shares of Bluebird Bio in a report on Friday, September 23rd. Finally, Wedbush restated an “outperform” rating and set a $117.00 price target on shares of Bluebird Bio in a report on Monday, October 3rd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $90.25.

Analyst Recommendations for Bluebird Bio (NASDAQ:BLUE)

Shares of Bluebird Bio (NASDAQ:BLUE) traded up 0.23% during mid-day trading on Thursday, hitting $65.70. The stock had a trading volume of 1,197,508 shares. The company’s market cap is $2.44 billion. The firm’s 50 day moving average price is $63.09 and its 200-day moving average price is $50.71. Bluebird Bio has a one year low of $35.37 and a one year high of $99.70.

Bluebird Bio (NASDAQ:BLUE) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported ($1.59) earnings per share for the quarter, missing the consensus estimate of ($1.44) by $0.15. Bluebird Bio had a negative return on equity of 24.85% and a negative net margin of 3,512.13%. The firm had revenue of $1.55 million for the quarter, compared to analysts’ expectations of $2.01 million. During the same quarter in the previous year, the firm posted ($1.57) earnings per share. The company’s revenue for the quarter was down 68.6% on a year-over-year basis. On average, equities research analysts anticipate that Bluebird Bio will post ($6.19) earnings per share for the current fiscal year.

In other news, insider David Davidson sold 1,000 shares of the company’s stock in a transaction dated Friday, July 15th. The shares were sold at an average price of $45.08, for a total transaction of $45,080.00. Following the completion of the transaction, the insider now owns 10,600 shares of the company’s stock, valued at $477,848. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Eric Sullivan sold 2,807 shares of the company’s stock in a transaction dated Wednesday, July 20th. The shares were sold at an average price of $45.04, for a total transaction of $126,427.28. Following the transaction, the insider now directly owns 4,656 shares of the company’s stock, valued at approximately $209,706.24. The disclosure for this sale can be found here. Insiders own 3.50% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in BLUE. Seven Eight Capital LLC bought a new position in shares of Bluebird Bio during the first quarter worth approximately $108,000. Quantbot Technologies LP boosted its stake in Bluebird Bio by 431.3% in the second quarter. Quantbot Technologies LP now owns 2,848 shares of the company’s stock worth $123,000 after buying an additional 2,312 shares during the last quarter. First Mercantile Trust Co. acquired a new stake in Bluebird Bio during the third quarter worth $129,000. BlackRock Inc. boosted its stake in Bluebird Bio by 341.0% in the first quarter. BlackRock Inc. now owns 4,569 shares of the company’s stock worth $194,000 after buying an additional 3,533 shares during the last quarter. Finally, BNP Paribas Arbitrage SA boosted its stake in Bluebird Bio by 110.5% in the third quarter. BNP Paribas Arbitrage SA now owns 3,084 shares of the company’s stock worth $209,000 after buying an additional 1,619 shares during the last quarter.

Bluebird Bio Company Profile

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

5 Day Chart for NASDAQ:BLUE

Receive News & Stock Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related stocks with our FREE daily email newsletter.